NCT05011396Phase 3Terminated

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2

Study sponsor: VistaGen Therapeutics, Inc. · VTGN

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-08-16Actual

Enrollment · participants228Actual

Source updated2025-11-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-11-24 · 1 field changed

Actual enrollment increased by 87 participants

− Before

~~141 participants (actual)~~

+ After

228 participants (actual)

Check registry source

Study details

Conditions studied

Social Anxiety Disorder

Treatments or interventions studied

PH94B Nasal SprayDrug
Placebo Nasal SprayDrug

Primary outcomes · main study measures

measure: Subjective Units of Distress Scale (SUDS); description: The SUDS is a patient self-rated scale that is scored in the range of 0 to 100 (operationalized for participants in this study as 0=totally relaxed or no anxiety and 100=highest distress or anxiety ever felt; timeFrame: Visit 2 (Baseline; Day 0) to Visit 3 (Day 7 ± 2 days)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history